Docoh
Loading...

RGLS Regulus Therapeutics

News

From Benzinga Pro
5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More
27 Jan 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates of 5.5%. Investors, meanwhile, focused on some notable insider trades.
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
21 Jan 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder
21 Jan 22
Biotech, News, Penny Stocks, Health Care, FDA, General
Regulus Therapeutics Inc (NASDAQ: RGLS) has
Regulus Therapeutics Reports Successful Completion Of Pre-Investigational New Drug Meeting With FDA For RGLS8429
20 Jan 22
Biotech, News, FDA, General
Company remains on track to submit IND and initiate Phase 1 study in second quarter 2022 Company to include evaluation of treatment impact on slowing cystic kidney expansion SAN DIEGO, Jan. 20, 2022 /PRNewswire/
Stocks That Hit 52-Week Lows On Wednesday
12 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 41 stocks made new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
Stocks Hitting New 52-Week Lows Today
3 Jan 22
News, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 60 companies achieved new lows for the year.
Regulus Therapeutics Announces Presentation At First Annual Rare & Genetic Kidney Disease Drug Development Summit
1 Dec 21
News, FDA, Events
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today
Regulus Therapeutics Announces Private Placement Of Equity Of ~$34.6M
24 Nov 21
News
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today
Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate
10 Nov 21
Earnings, News
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Regulus Therapeutics Granted US Patent 'Methods for treatment of polycystic kidney disease'
9 Nov 21
Biotech, General
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4848&f=G&l=50&d=PTXT&p=97&S1=20211109&OS=20211109&RS=20211109

Press releases

From Benzinga Pro
Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429
20 Jan 22
Press Releases
SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development
3 Dec 21
Press Releases
SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit
1 Dec 21
Press Releases
SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity
30 Nov 21
Press Releases
SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
Regulus Therapeutics Announces Private Placement of Equity
24 Nov 21
Press Releases
LA JOLLA, Calif., Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the
Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
10 Nov 21
Earnings, Press Releases
SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or
Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call
3 Nov 21
Press Releases
SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or